CA-WILSON-SONSINI
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jindrich Kloub has joined the firm’s antitrust and competition department as a partner in the Brussels office. Kloub’s more than 10 years of service at the European Commission’s Directorate-General for Competition and his most recent Hong Kong Competition Commission (HKCC) role illustrate the range of his enforcement agency experience and connections. His addition fortifies Wilson Sonsini’s acclaimed antitrust and competition practice in the United States and Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005164/en/
Jindrich Kloub, Partner, Wilson Sonsini (Photo: Business Wire)
Most recently, Kloub was executive director of operations at the HKCC, where he was responsible for all antitrust enforcement since 2017. In this role, he oversaw numerous precedent-setting investigations, including one that led to the HKCC’s first abuse of dominance enforcement action, as well as its first enforcement outcomes involving resale price maintenance, digital markets, leniency, settlements, commitments, director disqualifications and compliance remedies.
Kloub also has substantial international antitrust and competition policy experience. For example, in addition to leading the development of a fining methodology and cooperation and commitments policies, he oversaw major revisions to the HKCC’s leniency guidelines, which have been described within the private antitrust and competition bar as a world-class policy.
Before joining the HKCC, Kloub worked as an attorney at the European Commission’s Directorate-General for Competition (DG COMP) for more than a decade. During that time, he conducted numerous international cartel investigations, including major international cartel investigations in the financial services sector involving LIBOR and Forex benchmark rates.
“Because Hong Kong’s competition law was based on EU competition law, Jindrich has worked at two enforcement agencies that are highly engaged in monitoring and enforcing competition and antitrust laws of importance to our clients,” said Doug Clark, managing partner, Wilson Sonsini. “Jindrich’s enforcement and policy experience is the ideal combination to complement our already highly regarded antitrust and competition practice. We’re very excited to welcome him to the firm.”
Kloub’s addition comes just over a year and a half after Wilson Sonsini announced that Brent Snyder was joining the firm’s antitrust and competition practice on March 1, 2021. Snyder also joined the firm from the HKCC, having served as its CEO from 2017 through 2020.
“I’m pleased to be joining Wilson Sonsini’s accomplished competition and antitrust team, and excited about my role in helping the firm continue to expand its impressive, global practice and presence in Europe,” said Kloub. “This position not only gives me a chance to apply my enforcement and policy experience to help clients manage matters in both Europe and the U.S., but it’s also an exciting opportunity to work with Wilson Sonsini’s impressive range of clients.”
“Jindrich’s addition to our Brussels office further demonstrates Wilson Sonsini’s growing presence and strong brand in Europe – especially within the complex and constantly changing digital regulatory framework that impacts both antitrust and data protection,” said Cedric Burton, managing partner of Wilson Sonsini’s Brussels office. “Our growing team will be able to offer a new level of service and expertise on the ground to our clients within the European Union.”
Kloub earned his Master of Laws from Charles University School of Law in Prague in 2003 and his LL.M. from Columbia Law School in 2009. He has served as a visiting professor of competition law at Lille’s Catholic University for more than a decade, spoken widely at international conferences, and written numerous articles on competition law.
About Wilson Sonsini Goodrich & Rosati
For more than 60 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, please visit www.wsgr.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
